Catherine Kacprzycki

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

Founded in 1991 by Philip Paul, Paul Capital Partners LP is a private equity firm located in San Francisco with additional offices in New York City, Hong Kong, London, Paris and São Paulo.

BVP Partners LLC (BVP Partners) is a venture capital firm founded in the year 2003. The firm headquarters in Princeton.

Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD.

Dialysis Clinic, Inc. provides health care services. The company was founded by H. Keith Johnson in 1971 and is located in Nashville, TN.

Appleton Medical Center, Inc. provides cardiac, cancer and orthopedic care services. The firm also provides radiation oncology, stereotactic radiotherapy and radio surgery. The company was founded in 1958 and is headquartered in Appleton, WI.

INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ.

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from explicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bio products. Recombinant therapeutic proteins have proven to be invaluable biopharmaceuticals for the treatment of chronic and life-threatening diseases. While exceptionally effective, the dosage requirements are generally very high for the required treatment. Several hundred milligrams of protein per administration is common and multiple doses are often required and being protein based drugs, they can only be produced by living cells which is why increasing production yield is a challenge. CDI Bioscience has developed a patented technology that dramatically improves the product yield in biopharmaceutical manufacturing. CDI's core technology, RP Shift®, solves a number of intermediate problems in the development of biopharmaceutical products by significantly boosting the productivity and viability of production cells.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Inomax LLC is an American venture capital company.

Part of General Electric Co., Datex-Ohmeda, Inc. develops and manufactures medical equipment. The private company is based in Madison, WI.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.

The Capital Network, Inc. is a private company based in Wellesley, MA that provides founder-focused fundraising education programs. The company aims to create a more inclusive and accessible funding ecosystem to support female and other first-time founders of early stage startups. The company offers three programs: the Fellowship for Female Founders, Fundraising Readiness Workshops, and the Investment and Inclusion Series. The Fellowship for Female Founders is a six-month program that has helped over 90+ female founders raise over $85m in capital. The company also offers ongoing workshops for first-time startup founders and a series of honest conversations to bring about meaningful systemic change. The Capital Network has a network of 300+ investors and sponsors who help them make the fundraising ecosystem work for everybody. The company was founded by Ashkan Afkhami and Chula Reynolds.

Cerium Pharmaceuticals, Inc. develops and commercializes medicines for rare and ultra-rare diseases. The company was founded by Gregg Anthony Lapointe and is headquartered in Gaithersburg, MD.

Adaptive Phage Therapeutics, Inc. provides therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company was founded by Gregory L. Merril and Carl R. Merril and is headquartered in Bethesda, MD.

Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.